Lymfom - Klinisk forskning

Organisation: forskargrupp

Fler filtreringsmöjligheter
  1. 2019
  2. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

    Biccler, J. L., Glimelius, I., Eloranta, S., Smeland, K. B., Brown, P. D. N., Jakobsen, L. H., Frederiksen, H., Mats Jerkeman, Fosså, A., Andersson, T. M. L., Holte, H., Bøgsted, M., El-Galaly, T. C. & Smedby, K. E., 2019 mar 20, I : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 9, s. 703-713 11 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

    Solans, M., Benavente, Y., Saez, M., Agudo, A., Naudin, S., Hosnijeh, F. S., Noh, H., Freisling, H., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Rodríguez-Barranco, M., Amiano, P., Huerta, J. M., Barricarte, A. & 26 andraSchmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Bamia, C., Peppa, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Panico, S., Skeie, G., Weiderpass, E., Mats Jerkeman, Ulrika Ericson, Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Bolvig, A. K., Tjønneland, A., de Sanjose, S., Buckland, G., Vermeulen, R., Nieters, A. & Casabonne, D., 2019, I : International Journal of Cancer. 145, 1, s. 122-131

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

    Fredrik Ellin, Maurer, M. J., Srour, L., Farooq, U., Mats Jerkeman, Connors, J. M., Smedby, K. E., Bennani, N. N., Ansell, S. M., Slack, G. W., Cerhan, J. R., Relander, T., Feldman, A. L. & Savage, K. J., 2019, I : British Journal of Haematology.

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  5. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study

    T. Wästerlid, Mohammadi, M., Smedby, K. E., Glimelius, I., M. Jerkeman, Bottai, M. & Eloranta, S., 2019, I : Journal of Internal Medicine. 285, 4, s. 455-468

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition

    Costas, L., Lujan-Barroso, L., Benavente, Y., Allen, N. E., Amiano, P., Ardanaz, E., Besson, C., Boeing, H., Bueno-de-Mesquita, B., Cervenka, I., Fortner, R. T., Fournier, A., Gunter, M., Harlid, S., Huerta, J. M., Jerkeman, M., Jirström, K., Kaaks, R., Karakatsani, A., Khaw, K. T. & 22 andraKotanidou, A., Lund, E., Masala, G., Mattiello, A., Melin, B., Menéndez, V., Murphy, N., Nieters, A., Overvad, K., Riboli, E., Sacerdote, C., Sánchez, M. J., Schmidt, J. A., Sieri, S., Tjønneland, A., Trichopoulou, A., Tumino, R., Vermeulen, R., Weiderpass, E., de Sanjosé, S., Agudo, A. & Casabonne, D., 2019, I : American Journal of Epidemiology. 188, 2, s. 274-281 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. 2018
  8. Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of followup

    Hagström, H., Andreasson, A., Carlsson, A. C., Mats Jerkeman & Carlsten, M., 2018 aug 23, I : PLoS ONE. 13, 8, e0202651.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  9. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

    Ekberg, S., Mats Jerkeman, Andersson, P. O., Enblad, G., Wahlin, B. E., Hasselblom, S., Andersson, T. M., Eloranta, S. & Smedby, K. E., 2018 aug 1, I : American Journal of Hematology. 93, 8, s. 1020-1028 9 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Rule, S., Jurczak, W., M. Jerkeman, Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S. G., Thieblemont, C., Zhou, W., Henninger, T., Goldberg, J., Vermeulen, J. & Dreyling, M., 2018 aug, I : Leukemia. 32, 8, s. 1799-1803

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): A multicentre, open-label, single-arm, phase 2 trial

    Mats Jerkeman, Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., Kuitunen, H., Geisler, C. H., Grønbæk, K. & Kolstad, A., 2018 mar, I : The Lancet Haematology. 5, 3, s. e109-e116

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  12. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: A critical assessment of the R-IPI, IPI, and NCCN-IPI

    Biccler, J., Eloranta, S., de Nully Brown, P., Frederiksen, H., Mats Jerkeman, Smedby, K. E., Bøgsted, M. & El-Galaly, T. C., 2018 jan, I : Cancer Medicine. 7, 1, s. 114-122

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study

    Fredrik Ellin, Mats Jerkeman, Törnqvist, J., Brudin, L. & Relander, T., 2018, I : Hematological Oncology. 36, 1, s. 159-165

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  14. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Eskelund, C. W., Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Pedersen, L. B., Geisler, C. H., Mats Jerkeman & Grønbæk, K., 2018, I : Haematologica. 103, 11, s. e541-e543

    Forskningsoutput: TidskriftsbidragLetter

  15. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

    Dang, N. H., Ogura, M., Castaigne, S., Fayad, L. E., Mats Jerkeman, Radford, J., Pezzutto, A., Bondarenko, I. N., Stewart, D. A., Shnaidman, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P. A., Giné, E. & Ando, K., 2018, I : British Journal of Haematology. 182, 4, s. 583-586

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  16. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

    Dreyling, M., Aurer, I., Cortelazzo, S., Hermine, O., Hess, G., Mats Jerkeman, Le Gouill, S., Ribrag, V., Trněný, M., Visco, C., Walewski, J., Zaja, F. & Zinzani, P. L., 2018, I : Leukemia and Lymphoma. 59, 8, s. 1814-1828

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. 2017
  18. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

    Maurer, M. J., Fredrik Ellin, Srour, L., Mats Jerkeman, Bennani, N. N., Connors, J. M., Slack, G. W., Smedby, K. E., Ansell, S. M., Link, B. K., Cerhan, J. R., Relander, T., Savage, K. J. & Feldman, A. L., 2017 dec 20, I : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35, 36, s. 4019-4026 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  19. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

    Henrik Cederleuf, Hjort Jakobsen, L., Fredrik Ellin, de Nully Brown, P., Stauffer Larsen, T., Bøgsted, M., Relander, T., Mats Jerkeman & El-Galaly, T. C., 2017 dec 2, I : Leukemia and Lymphoma. 58, 12, s. 2815-2823 9 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  20. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

    Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Sara Ek, Pedersen, A., Niemann, C., Raty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Mats Jerkeman & Grønbæk, K., 2017 okt 26, I : Blood. 130, 17, s. 1903-1910 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  21. Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

    Hasni, M. S., Berglund, M., Yakimchuk, K., Guan, J., Linderoth, J., Amini, R-M., Enblad, G. & Okret, S., 2017 feb 1, I : Leukemia & Lymphoma. 58, 2, s. 418-427 10 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Frequency and clinical implications of SOX11 expression in Burkitt lymphoma

    Tove Wästerlid, Nordström, L., Freiburghaus, C., Pedersen, M., Nørgaard, P., Gang, A. O., Brown, P., Michael Dictor, Mats Jerkeman & Sara Ek, 2017, I : Leukemia & Lymphoma. 58, 7, s. 1760-1763 4 s.

    Forskningsoutput: TidskriftsbidragLetter

  23. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Dreyling, M., Campo, E., Hermine, O., M. Jerkeman, Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., Ladetto, M. & on behalf of the ESMO Guidelines Committee, 2017, I : Annals of Oncology. 28, s. iv62-iv71

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  24. Targeting of B-cell receptor signalling in B-cell malignancies

    M. Jerkeman, Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E. & Staudt, L., 2017, I : Journal of Internal Medicine. 282, 5, s. 415-428

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  25. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study

    Henrik Cederleuf, Bjerregård Pedersen, M., Mats Jerkeman, Relander, T., d'Amore, F. & Fredrik Ellin, 2017, I : British Journal of Haematology. 178, 5, s. 739-746

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  26. 2016
  27. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

    Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M-L., Sundström, C., Mats Ehinger, Geisler, C. & Mats Jerkeman, 2016 jun 27, I : Blood. 128, 14, s. 1814-1820

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  28. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms

    Tove Wästerlid, 2016, Lund: Lund University, Faculty of Medicine. 116 s.

    Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

  29. Högintensiv cytostatikaterapi ökade överlevnad vid burkitts lymfom

    Tove Wästerlid, 2016, I : Lakartidningen. 113, 48

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  30. 2015
  31. Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.

    Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattson, J., Sundberg, A., Vaughan, A. T., Shah, V., Smyth, N. R., Sheth, B., Chan, H. T. C., Li, Z-C., Williams, E. L., Manfredi, G., Oldham, R. J., Mockridge, C. I., James, S. A., Dahal, L. N. & 12 andraHussain, K., Björn Nilsson, Verbeek, J. S., Gunnar Juliusson, Markus Hansson, Mats Jerkeman, Johnson, P. W. M., Davies, A., Beers, S. A., Glennie, M. J., Frendéus, B. & Cragg, M. S., 2015, I : Cancer Cell. 27, 4, s. 473-488

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  32. Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.

    Fredrik Ellin, Landström, J., Mats Jerkeman & Relander, T., 2015, I : Blood. 126, 1, s. 36-41

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  33. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

    El-Galaly, T. C., Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Nilsson-Ehle, H., Erzsébet Szekely, Mylam, K. J., Hjalmar, V., Johnsen, H. E., Bøgsted, M. & Mats Jerkeman, 2015, I : Journal of Clinical Oncology. 33, 34, s. 3993-3998

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  34. 2014
  35. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

    Abrahamsson, A., Alexandra Albertsson Lindblad, Brown, P. N., Baumgartner-Wennerholm, S., Pedersen, L. M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H. & Mats Jerkeman, 2014, I : Blood. 124, 8, s. 1288-1295

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  36. Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

    Fredrik Ellin, Landström, J., Mats Jerkeman & Relander, T., 2014, I : Blood. 124, 10, s. 1570-1577

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  37. Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry

    Ellin, F., Mats Jerkeman, Hagberg, H. & Relander, T., 2014, I : Acta Oncologica. 53, 7, s. 927-934

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  38. 2013
  39. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.

    Tove Wästerlid, Brown, P. N., Oskar Hagberg, Hagberg, H., Pedersen, L. M., D'Amore, F. & Mats Jerkeman, 2013, I : Annals of Oncology. 24, 7, s. 1879-1886

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  40. 2012
  41. Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma

    Fjordén, K., Joost, P., Mats Ehinger, Patrik Edén, Mats Jerkeman, Cavallin-Ståhl, E. & Linderoth, J., 2012, I : Leukemia & Lymphoma. 53, 9, s. 1764-1768

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  42. 2010
  43. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

    Fjordén, K., Linderoth, J., Nyman, H., Mats Ehinger, Joost, P., Pär-Ola Bendahl, Leppä, S. & Mats Jerkeman, 2010, I : Leukemia & Lymphoma. 51, s. 1643-1648

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  44. 2008
  45. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.

    Linderoth, J., Patrik Edén, Mats Ehinger, Valcich, J., Mats Jerkeman, Pär-Ola Bendahl, Berglund, M., Enblad, G., Erlanson, M., Roos, G. & Cavallin-Ståhl, E., 2008, I : British Journal of Haematology. 141, 4, s. 423-432

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift